• Reports are circulating related to recurring COVID-19 symptoms after completing treatment and experiencing improvement after Pfizer Inc's (NYSE: PFE) COVID-19 oral antiviral Paxlovid.

• President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking Paxlovid.

• The U.S. government researchers have found that the rebound may be related to a robust immune response rather than a weak one, Reuters reports.

• Also read: Pfizer's COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows.

• The researchers concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence, based on an investigation of a rebound in eight patients at the National Institutes of Health's Clinical Center.

• The FDA asked Pfizer to test an additional course of Paxlovid among people who experience a rebound in COVID-19 after treatment.

• The repot added that all patients in the study had developed robust immune responses but higher levels of antibodies in the patients who experienced a rebound.

• None of the rebound patients required additional treatment or hospitalization.

• Price Action: PFE shares are down 1.57% at $42.42 on the last check Friday.

See more from Benzinga

• Pfizer In-Licenses Voyager Therapeutics' AAV Capsid For Rare Neurologic Disease Target

• Pfizer Touts Positive Data From Prostate Cancer Combo Therapy Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.